Lorundrostat Placebo Tablets, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat
MLS-101-301
Phase 3 small_molecule active
Quick answer
Lorundrostat Placebo Tablets, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat for Uncontrolled and Resistant Hypertension is a Phase 3 program (small_molecule) at Mineralys Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mineralys Therapeutics
- Indication
- Uncontrolled and Resistant Hypertension
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active